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Background: Hypoxia is often encountered in solid tumors and known to contribute to aggressive tumor behavior,
radiation- and chemotherapy resistance resulting in a poor prognosis for the cancer patient. MicroRNAs (miRNAs)
play a role in the regulation of the tumor cell response to hypoxia, however, not much is known about the
involvement of miRNAs in hypoxic signalling pathways in soft tissue sarcomas (STS).
Method: A panel of twelve STS cell lines was exposed to atmospheric oxygen concentrations (normoxia) or 1%
oxygen (hypoxia) for up to 48 h. Hypoxic conditions were verified and miRNA expression profiles were assessed by
LNA™ oligonucleotide microarrays and RT-PCR after 24 h. The expression of target genes regulated by hypoxia
responsive miRNAs is examined by end-point PCR and validated by luciferase reporter constructs.
Results: Exposure of STS cell lines to hypoxic conditions gave rise to upregulation of Hypoxia Inducible Factor
(HIF) 1α protein levels and increased mRNA expression of HIF1 target genes CA9 and VEGFA. Deregulation of
miRNA expression after 24 h of hypoxia was observed. The most differentially expressed miRNAs (p < 0.001) in
response to hypoxia were miR-185-3p, miR-485-5p, miR-216a-5p (upregulated) and miR-625-5p (downregulated).
The well-known hypoxia responsive miR-210-3p could not be reliably detected by the microarray platform most
likely for technical reasons, however, its upregulation upon hypoxic stress was apparent by qPCR. Target prediction
algorithms identified 11 potential binding sites for miR-485-5p and a single putative miR-210-3p binding site in the
3’UTR of HIF3α, the least studied member of the HIF family. We showed that HIF3α transcripts, expressing a 3’UTR
containing the miR-485-5p and miR-210-3p target sites, are expressed in all sarcoma cell lines and upregulated
upon hypoxia. Additionally, luciferase reporter constructs containing the 3’UTR of HIF3α were used to demonstrate
regulation of HIF3α by miR-210-3p and miR-485-5p.
Conclusion: Here we provide evidence for the miRNA mediated regulation of HIF3α by hypoxia responsive miRNAs
in STS, which may help to tightly regulate and fine-tune the hypoxic response. This provides a better insight into
the mechanisms underlying the hypoxic response in STS and may ultimately yield information on novel prognostic
and predictive markers or targets for treatment.
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Hypoxia is a condition of reduced oxygen tension that is
often encountered in solid tumors including soft tissue
sarcomas (STS) when they outgrow their blood supply.
The tumor cells respond to the hypoxic conditions by
inducing genes that regulate various biological processes
including cellular proliferation, apoptosis, metabolism,
angiogenesis and migration [1]. A key element in the re-
sponse to hypoxia is the upregulation of HIF1, a member
of the family of hypoxia inducible factors (HIFs) also
comprising HIF2 and HIF3 [2]. These transcription fac-
tors consist of a tightly controlled alpha (HIFα), and a
constitutively activated beta subunit (HIFβ or ARNT
family). Upon hypoxia, the alpha subunit is stabilized,
translocated to the nucleus, where it dimerizes to the
beta subunit. The HIF complex binds to hypoxia respon-
sive elements (HREs) in gene promoters, thereby in-
ducing the transcription of genes important for the
adaption to low oxygen concentrations. HIF1α and
HIF2α have similar protein domain structures, are regu-
lated in a similar fashion and share several target genes
[3], although their expression patterns differ in some tis-
sues and some unique target genes have been identified
[4]. The function(s) of HIF3α and the way it is regulated
are still largely unknown. Complicating the study of
HIF3α is the fact that alternative splice variants are rec-
ognized coding for at least six isoforms, with structural
and functional differences [5-7]. HIF3α is regulated by
HIF1 at the transcriptional level and exerts an inhibitory
effect on HIF1α or HIF-dependent gene regulation, in a
cell-type specific manner [5-11].
Tumor hypoxia and the accompanying biochemical
and cellular changes in the tumor cells contribute to ag-
gressive tumor behavior, and radiation- and chemother-
apy resistance in many tumor types, including STS
[12,13]. STS is a group of relatively rare tumors of mes-
enchymal origin in which currently more than 50 differ-
ent histological subtypes are recognized. STS have been
reported to present with hypoxic areas resulting in in-
creased tumor proliferation, distant metastases and
shorter overall disease survival [14,15]. Given the poor
prognosis STS patients face with, a median overall sur-
vival of only 1 year for patients presenting with meta-
static disease, more insight is needed into the effects of
hypoxia in STS and how hypoxia is regulated in STS.
MicroRNAs (miRNAs) are small (~23 nt) non-protein
coding RNA molecules that negatively regulate gene ex-
pression. MiRNAs play essential roles in a wide variety
of cellular processes, such as differentiation, cell cycle
regulation, metabolism, apoptosis and stem cell main-
tenance and are associated with various diseases includ-
ing cancer [16]. Most cancers display a deregulated
miRNA expression profile when compared to relevant
normal tissues. Some miRNAs may function as anoncomiR, having either a tumor suppressive or an onco-
genic role [17-20]. MiRNA expression can be influenced
by changes in the tumor microenvironment [21,22] in-
cluding conditions like tumor hypoxia [23-26]. The
miRNA response to hypoxia, which is often cell-type
specific, suggests miRNAs are intimately involved in the
cellular reaction to hypoxia [23,24,26] and some are in
turn involved in feedback mechanisms that regulate HIF
[27-32]. Interestingly, many hypoxia responsive miRNAs
(HRMs) are also upregulated in cancer suggesting they
also function in tumorigenesis and/or tumor progression
[26]. As opposed to the role of HRMs in the major can-
cer types relatively little is known about the role of hyp-
oxic miRNAs in STS. In this study, we describe the
miRNA response to hypoxic stress in sarcoma cell lines
revealing the involvement of miRNAs in the hypoxic
signalling in STS.Methods
Cell culture
A panel of 12 soft tissue sarcoma cell lines was used,
consisting of the fibrosarcoma cell lines HT1080, SW684
and BG-8, the liposarcoma cell line SW872, the leiomyo-
sarcoma cell lines SK-UT-1 and SK-LMS-1, the synovial
sarcoma cell line SW982 and the rhabdomyosarcoma
cell lines RH30, A204, A673, RD and SJCRH30. Note
that the A673 (ATCC®CRL-1598) cell line is now listed
on the ATCC website as Ewing sarcoma. The myxoid
fibrosarcoma cell line BG-8 was a kind gift from Dr. A.
Carnero (Centro Nacional de Investigaciones Oncológicas,
Madrid, Spain); HT1080, SK-UT-1, RD and RH-30 were
acquired from Dr. M. Debiec-Rychter (KU Leuven, Leu-
ven, Belgium) and SJCRH30 was obtained from Dr. L.
Alberti (Université de Lyon, Centre Léon Bérard, Lyon,
France). All further cell lines were obtained from the
ATCC, Rockville, MD, USA. The cell lines were cultured
in RPMI 1640/GlutaMAX (Invitrogen, Bleiswijk, The
Netherlands) supplemented with 10% fetal bovine serum,
at 37°C, 5% CO2.Hypoxic experiments
The 12 cell lines comprising the soft tissue sarcoma
panel were cultured under standard conditions and
seeded in 6 well culture plates or 9 cm cell culture
dishes (miRNA profiling experiment) in duplicate at
such a cell density that 50% confluency was reached
after 48 h. Subsequently half of the culture plates was
kept under standard, normoxic (21% O2) culture condi-
tions whereas the other half was transferred to a hypoxic
incubator and cultured at 37°C, 5% CO2, 1% O2 for 6 h
to 48 h as indicated. After the appropriate normoxic/
hypoxic incubation period cells were rapidly washed
with ice-cold PBS after which total RNA was isolated
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(three separate wells) were prepared.
RNA isolation
Total RNA was isolated using RNAbee (Tel Test Inc.,
Friendswood, TX, USA) according to the manufacturer’s
recommendation. The RNA concentration and quality
were determined on a Nanodrop-1000 (Nanodrop Tech-
nologies, Wilmington, DE, USA).
MiRNA microarray
MiRNA profiling was performed essentially as previously
described [33]. In brief, 1 μg total RNA was fluorescently
labeled with Cy3 using the ULS™ aRNA Labeling Kit
(Kreatech Diagnostics, Amsterdam, The Netherlands).
Labeled RNA was hybridized with locked nucleic acid
(LNA™) modified oligonucleotide capture probes (Exi-
qon) spotted in duplicate on Nexterion E slides. The
capture probe set (based on miRBase version 10, annota-
tion version 13) contains 1344 probes of which 725 are
capable of detecting human miRNAs. Hybridized slides
were scanned and median spot intensity was determined
using ImaGene software (BioDiscovery Inc., Hawthorne,
CA, USA). After background subtraction, expression
values were quantile normalized using R software
(http://cran.r-project.org; version 2.15.2, release oct.
2012), low expressed miRNAs and obvious outliers/bad
spots were removed, and duplicate spots were averaged.
Outliers/bad spots were identified by determining the
average expression value of each miRNA and examining
whether duplicate spots differ from the average (>2 ×
greater or >5 × smaller). Flagged spots were checked by
eye to determine why the signal is aberrant e.g. a speck
of dust or printing error. Only in case of an apparent
technical error, noted in less than 1% of the spots, a spot
was discarded. For each expression value, the ratio to the
geometric mean of the samples was log2 transformed.
These values were used to determine differentially
expressed miRNAs. Hierarchical clustering analyses were
performed in Spotfire (Spotfire DecisionSite 9.1, Tibco
Software, Somerville, MA. USA).
qPCR analysis of miRNA
MiR-210-3p expression was examined using TaqManW
MicroRNA Assays (Applied Biosystems, Nieuwerkerk
aan den IJssel, The Netherlands). In brief, total RNA
(50 ng) was reverse transcribed using specific miRNA
primers and the TaqManW MicroRNA Reverse Tran-
scription Kit (Applied Biosystems). The resulting cDNA
was used as input in a quantitative real-time PCR
(qPCR) using the miRNA specific primer/probe mix to-
gether with the TaqManW Universal PCR Master Mix
No AmpErase® UNG (Applied Biosystems) according to
manufacturer’s protocol. qPCR data were analyzed withSDS software (version 2.4, Applied Biosystems). MiRNA
expression was normalized using RNU43 expression and
the comparative CT-method [34].
cDNA-synthesis
RNA (1 μg) was reversed transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems) according to the manufacturer’s protocol. The
resulting cDNA was used to perform qPCR and end-
point PCR analysis.
qPCR analysis of mRNAs
cDNA (45 ng) was used to perform qPCR using the pri-
mer/probe mix from the TaqManW Gene Expression As-
says of human VEGFA (assay ID Hs00900055_m1) and
CA9 (assay ID Hs00154208_m1) with exon spanning
probes, and TaqManW Universal PCR Master Mix using
the 7500 Fast Real-Time PCR system (all Applied Bio-
systems) according to the manufacturer’s protocol.
HPRT was used as a housekeeper gene for normalization
purposes using the comparative CT-method. qPCR data
was analyzed with SDS software (Applied Biosystems).
End-point PCR analysis
cDNA (50 ng) was used to perform endpoint PCR using
1 × Green Go Taq Flexi Buffer, 1.25U Go Taq Flexi poly-
merase, 200 μM dNTP mix, 1.5 mM MgCl2 and 300 nM
forward and reverse primer of HIF3α (Additional file 1:
Table S1a) on a thermal cycler using the following PCR-
program: 2 min 95°C, 30-40 cycles of (45 sec 95°C,
45 sec 60-65°C, 45 sec 72°C), 5 min 72°C. PCR-products
were analyzed on a 1.5% agarose gel in 0.5 × TBE buffer
with 0.5 μg/ml ethidium bromide.
Protein extraction
Cells were harvested in MCB lysis buffer (50 mM Tris–
HCl pH 7.5, 50 mM NaCl, 10% glycerol, 1% NP-40, 0.5%
Na-deoxycholate, 20 mM NaF) supplemented with a
cocktail of protease and phosphatase inhibitors. Lysates
were thoroughly vortexed and further lysed by two sub-
sequent freeze-thaw cycles using liquid nitrogen. Cell
debris was spun down and protein concentration was
determined by a Bradford assay (BioRad, Veenendaal,
The Netherlands).
Western blotting
Twenty μg of total protein was subjected to SDS-PAGE.
Proteins were transferred to a PVDF membrane followed
by blocking of the membrane in 5% non-fat dry milk in
PBS-Tween (Phosphate buffered saline, 0.05% (v/v) Tween
20) to prevent non-specific antibody binding. Primary and
secondary antibody incubations were carried out in the
same buffer using anti-HIF1α (610958, mouse monoclo-
nal, 1:500, BD Biosciences, Breda, The Netherlands), anti-
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bridge, UK) and anti-β-Actin (AC-15, mouse monoclonal,
1:5000, Sigma-Aldrich, Zwijndrecht, The Netherlands)
as a loading control. As secondary antibody HRP-
conjugated goat-anti-mouse (1:10000, Santa Cruz Bio-
technology, Heidelberg, Germany) or goat-anti-rabbit
(1:10000, Jackson Immunoresearch, Suffolk, UK) anti-
bodies were used. Antibody incubations were followed
by enhanced chemoluminescence (Supersignal West
Pico Chemiluminescent Substrate, Thermo Scientific)
and visualized on film (Amersham Hyperfilm ECL, GE
Healthcare, Diegem, Belgium).
Mimic transfections
MiRIDIAN microRNA mimics (Thermo Scientific, Etten-
Leur, Netherlands) of hsa-miR-210-3p and hsa-miR-485-
5p and miRIDIAN microRNA Mimic Negative Control
#1 (Thermo Scientific) were transfected in a final concen-
tration of 50 nM using DharmaFECT1 transfection
reagent (Thermo Scientific) 24 h after cell seeding.
Transfection efficiency was optimized to >95% using
fluorescent mimics.
Cloning
Fragments of the 3’UTR of HIF3α (HIF3α-short: 817 bp
fragment, HIF3α-long: 3807 bp fragment) were PCR
amplified from human genomic DNA (Promega, Leiden,
The Netherlands) introducing a XhoI (5’-end) and a
NotI site (3’-end). The PCR products were cloned in
PCR®-Blunt (Invitrogen), followed by a XhoI and NotI
restriction and ligation in the psiCHECK™-2 vector (Pro-
mega) behind a Renilla luciferase gene. The psiCHECK-
2 vector also contains a firefly luciferase gene, which was
used for normalization. The resulting constructs are psi-
CHECK2/HIF3α-short and psiCHECK2/HIF3α-long. Site
directed mutagenesis (QuickChange II XL, site directed
mutagenesis kit, Agilent Technologies, Amsterdam, The
Netherlands) was performed to mutate miR-210-3p and
miR-485-5p target sites in the 3’UTR of HIF3α in psi-
CHECK2/HIF3α-short (Additional file 1: Figure S1). Pri-
mer sequences used for cloning and mutagenesis are
listed in Additional file 1: Table S1b and S1c.
Luciferase assay
PsiCHECK-2/HIF3α-short and psiCHECK2/HIF3α-long
constructs were transfected using Fugene HD transfec-
tion reagent (Promega) 24 h after cell seeding, or when
mimics were used, 24 h after miRNA mimic transfec-
tion, according to recommendations by the manufac-
turer. After 24 hours the cells were washed with PBS
and lysed by Passive Lysis Buffer (Dual LuciferaseW Re-
porter Assay System, Promega) for 30 min on a shaker
platform. Lysates were transferred to white 96-wells mi-
croplates. Luciferase Assay Reagent II (Dual LuciferaseWReporter Assay System, Promega) was added, immedi-
ately followed by quantitation of the firefly luciferase
activity on a luminometer (Aspekt Fluoroskan). Subse-
quently, Stop & GloW Reagent (Dual LuciferaseW Reporter
Assay System, Promega) was added to the mixture, imme-
diately followed by quantitation of the Renilla luciferase
activity. Relative luciferase signals of duplicates were aver-
aged, values (n = 3) were normalized, and average and
standard deviations were calculated. Significant differ-
ences in luciferase activity were determined by two-
sample t-tests.
Detection of HRE in miRNA promoter regions
To determine whether the putative promoter regions of
miR-216a-5p, miR-185-3p and miR-625-5p contain hyp-
oxia responsive elements (HRE) we downloaded 600 bp
of 5’ flanking sequences for each of the three miRNA
genes from the Ensembl Genome Browser release 72
(http://www.ensembl.org). We scanned the flanking se-
quences for the presence of consensus HREs (A/GCGTG)
and imperfect HREs.
Results
Hypoxia responsive miRNAs in soft tissue sarcoma cells
In order to examine the miRNA response to hypoxia in
sarcomas, a panel of 12 soft tissue sarcoma cell lines was
cultured for 0 h, 6 h, 24 h and 48 h under hypoxic (1%
oxygen) or normoxic (21% oxygen) conditions. Exposure
to hypoxic conditions was verified by the upregulation
of HIF1α protein levels, which is one of the earliest
markers of hypoxia. HIF1α protein, being degraded
under normoxic conditions, is stabilized during hypoxia.
As expected, HIF1α protein levels were significantly in-
creased upon hypoxic stress (Figure 1A). In all 12 cell
lines examined peak HIF1α levels were observed at the
6 h time point which decreased after 24 h and 48 h
of hypoxia as shown for 5 representative cell lines
(Figure 1A). As a consequence of HIF1α upregulation,
the transcription of specific HIF1 target genes like CA9
and VEGFA was slightly induced after 6 h and further
increased after 24-48 h of hypoxia, as shown for 5 repre-
sentative cell lines (Figure 1B, C). Note that in particular
the increase in CA9 varies considerably between cell
lines. The carbonic anhydrase CA9 is a member of a
zinc metalloenzyme family that catalyses the reversible
hydration of carbon dioxide to carbonic acid [35,36].
CA9 is a transmembrane protein which is found overex-
pressed in numerous tumor types and induced under
hypoxic conditions. Similarly HIF1α stimulates the ex-
pression of the vascular endothelial growth factor
(VEGFA) which functions as an signal mediating vascu-
logenesis and angiogenesis [37].
Next, the miRNA expression profile was analyzed using
microarrays containing LNA™ oligonucleotide capture
Figure 1 Hypoxia induces HIF1α protein levels and CA9 and VEGFA transcription in soft tissue sarcoma cell lines. (A) HIF1α protein
levels are stabilized and increase during hypoxia. Cell lines were cultured under hypoxia (H) or normoxia (N), after the indicated times cell lysates
were prepared and analysed by Western blotting for HIF1α expression. HIF1α levels peak at 6 hours of hypoxia. Upon prolonged hypoxia (24 and
48 hours) HIF1α protein levels decrease, but remain increased compared to the HIF1α levels detected in cells cultured under normoxic
conditions. β-Actin was used as a loading control. (B,C) mRNA levels of HIF1 target genes CA9 (B) and VEGFA (C) are upregulated during hypoxia
(grey bars) compared to normoxia (black bars). CA9 and VEGFA expression was determined by RT-PCR and normalized to the expression of HPRT.
Bars indicate average fold change of mRNA expression ± S.D.(n = 2) compared to the levels detected at 0 h which are arbitrarily set at 1. Statistical
significance between CA9 and VEGF expression in normoxic and hypoxic samples at the various time points was determined by two-sample
t-tests: * = p < 0.05, ** = p < 0.005, *** = p < 0.0005. The complete panel of 12 soft tissue sarcoma cell lines was examined, the results obtained with
five representative cell lines are shown.
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Since HIF1 target genes were clearly induced after 24 h of
hypoxia, miRNA expression levels of cell lines that were
cultured for 24 h under normoxic or hypoxic conditionswere compared. Unsupervised hierarchical clustering
based on the miRNA expression profiles of 407 miRNAs
grouped the cell lines on cell type rather than on
exposure to hypoxia (Figure 2A), which implies that the
Figure 2 (See legend on next page.)
Gits et al. BMC Cancer 2014, 14:429 Page 6 of 13
http://www.biomedcentral.com/1471-2407/14/429
(See figure on previous page.)
Figure 2 Hypoxia induces changes in miRNA expression. (A) Unsupervised hierarchical clustering using miRNA expression data (407 miRNAs)
of hypoxic (H) and normoxic (N) cell line samples does not discriminate the hypoxic and normoxic samples. The hypoxic samples cluster together
with their normoxic counterparts. (B) The most significant differentially expressed miRNAs (two-sample t-test, p < 0.05) between cell lines that
were cultured under normoxic and hypoxic conditions are used for a supervised hierarchical clustering. The expression of these 32 miRNAs
can distinguish hypoxic from normoxic sarcoma cell line samples. (C) The four most significant (P < 0.001) differentially expressed miRNAs
(miR-485-5p, miR-216a-5p, miR-185-3p and miR-625-5p) discriminate sarcoma cell lines that were cultured under normoxic conditions from those
cultured under hypoxic conditions in a supervised hierarchical clustering. (D) MiR-210-3p is upregulated during hypoxia. RT-PCR was used to
determine miR-210-3p levels in normoxic (black bars) and hypoxic (grey bars) samples from five representative sarcoma cell lines. Expression is
normalized against RNU43 expression. Bars indicate average expression fold change ± S.D. (n = 2) of miR-210-3p compared to the expression
at 0 h. Statistical significance between expression in normoxic and hypoxic samples at a time point were determined by two-sample t-tests:
* = p < 0.05, ** = p < 0.005, *** = p < 0.0005. The different cell lines are indicated by a color code that identifies their tumor of origin: with synovial
sarcoma (yellow); Ewing sarcoma (green); rhabdomyosarcoma (purple); leiomyosarcoma (blue); liposarcoma (orange) and fibrosarcoma (red).
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tively minor. One major cluster branch contains the
rhabdomyosarcoma cell lines and the synovial sarcoma
cell line, the other branch contains the other cell lines
(leiomyosarcoma, liposarcoma and fibrosarcoma cell
lines). Supervised hierarchical clustering using the 32 most
differentially expressed miRNAs (p < 0.05; Additional file
1: Table S2) between cell lines exposed to hypoxia or nor-
moxia clearly separated the hypoxic from the normoxic
samples (Figure 2B). Fifteen miRNAs were upregulated
during hypoxia, while 17 miRNAs were downregulated.
The SJCRH30 rhabdomyosarcoma cell line cultures under
hypoxia was the only sample that misclustered, which in-
dicates that the hypoxia induced miRNA response in this
cell line was apparently weak. The top four differentially
expressed miRNAs (p < 0.001) consisted of miR-185-3p,
miR-485-5p, miR-216a-5p and miR-625-5p (Figure 2C;
Additional file 1: Table S2). Only miR-625-5p was down-
regulated in most hypoxic samples, whereas the other
three miRNAs were predominantly upregulated. MiR-
210-3p, a commonly found hypoxia responsive miRNA
(HRM), was not reliably detected on our microarray plat-
form. Therefore the miR-210-3p expression in normoxic
and hypoxic sarcoma cell line samples was separately de-
termined by qPCR, which revealed a significant upregula-
tion of miR-210-3p in all cell lines after 24 h of hypoxia
(Figure 2D).
HIF3α transcripts are expressed and upregulated under
hypoxia in sarcoma cell lines
Candidate target genes for the most differentially
expressed miRNAs identified in the microarray analysis
were predicted using TargetScanHuman 6.2 (http://www.
targetscan.org/) [38]. When we focused on genes known
to play a role in the hypoxic response it was noted that
miR-485-5p has as much as 11 potential binding sites in
the 3’UTR of HIF3α, the less studied member of the family
of hypoxia inducible factors. Also miR-210-3p has a single
putative binding site in this transcript (Figure 3A). Several
human HIF3α transcripts exist due to alternative splicing,
coding for different HIF3α isoforms [5-7]. According tothe Ensembl Genome Browser release 72 (http://www.
ensembl.org) the HIF3α transcript variants 003 and 201
(consistent with HIF3α transcription variant 1, 2 and 3
according to GenBank (http://www.ncbi.nlm.nih.gov/
genbank)) contain a long 3’UTR of 3811 bp which in-
cludes the potential miR-210-3p and miR-485-5p binding
sites. In order to determine whether these transcripts are
expressed in our sarcoma cell line panel we used an
adapted RT-PCR procedure involving an end-point PCR
and specific primers located in the 3’UTR (primer sites are
indicated in Figure 3B, primer sequences are listed in
Additional file 1: Table S1a). HIF3α transcripts containing
a long 3’UTR harboring the mentioned miRNA binding
sites could be detected in all cell lines and were upregu-
lated in time under hypoxic conditions (Figure 3D).
MiR-485-5p and miR-210-3p target HIF3α
The effects of miR-210-3p and miR-485-5p overexpression
on HIF3α, protein levels were examined by immunoblot-
ting. The sarcoma cell lines SW872 (liposarcoma) and SK-
UT-1 (leiomyosarcoma) were transfected with mimics of
miR-210-3p, miR-485-5p or a scrambled negative con-
trol. 48 h post-transfection the cells were exposed to hyp-
oxia for 24 h to induce HIF3α. Figure 4A clearly shows
that overexpression of the miRNA mimics resulted in a
reduced induction of HIF3α when compared to the
HIF3α protein levels observed in cells transfected with a
scrambled control mimic (mneg). The detected HIF3α
protein has a relative molecular weight of approximately
70 kDa which is in line with the predicted molecular
weight of the HIF3α proteins encoded by the 003 or 201
HIF3α transcript variants.
To demonstrate that during hypoxia HIF3α is regulated
by hypoxia responsive miRNAs, a short (HIF3α-short,
817 bp) and a long (HIF3α-long, 3807 bp) fragment of
the HIF3α 3’UTR (variants 003/201) (Figure 3C) were
cloned in a psiCHECK2 luciferase reporter. The psi-
CHECK2/HIF3α-short construct encompassed the puta-
tive miR-210-3p binding site and the first miR-485-5p
binding site. The psiCHECK2/HIF3α-long construct
included an additional 10 potential binding sites for
Figure 3 The 3’UTR of HIF3α contains putative miR-210-3p and miR-485-5p binding sites and is expressed in sarcoma cell lines.
(A) Schematic representation of the 3’UTR of the HIF3α transcript variants 003 and 201 (http://www.ensembl.org, release 72). Depicted are
predicted target sites of miR-210-3p (open box) and miR-485-5p (black boxes). (B) Arrows indicate location of primers used to detect the presence
of HIF3α 3’UTR transcripts. A 212 bp and 313 bp amplification product indicate expression of the 3’UTR of HIF3α transcription variants 003 and
201. (C) Lines designate the HIF3α 3’UTR fragments (HIF3α-short, HIF3α-long) which were cloned into the psiCHECK-2 luciferase reporter to verify
regulation of HIF3α by miRNAs. (D) End-point RT-PCR was used to determine the presence of HIF3α 3’UTR transcripts and their induction upon
hypoxia. Depicted are EtBr stained PCR amplification fragments of 212 and 313 bp derived from HIF3α 3’UTR cDNA and an amplified 336 bp HPRT
fragment as input control. The results obtained with five representative cell lines are shown.
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transfected with the psiCHECK2/HIF3α-short and psi-
CHECK2/HIF3α-long constructs. The next day the cells
were exposed to hypoxia for 24 h, after which the lucifer-
ase activity in cell lysates was determined. Luciferase ac-
tivity in SW872 hypoxic lysates was reduced to 57% and
65% in the HIF3α-short and HIF3α-long transfectants,
respectively, when compared to the levels seen at nor-
moxic circumstances (Figure 4B, left panel). In the hyp-
oxic SK-UT-1 lysates the luciferase activity was decreased
to 79% and 67% in the HIF3α-short and HIF3α-long
transfectants, respectively (Figure 4B, right panel). These
results indicate that during 24 h hypoxia the 3’UTR
of HIF3α is targeted, most likely by hypoxia responsive
miRNAs, causing a reduction of the luciferase activity.
To examine whether downregulation of HIF3α is medi-
ated by miR-210-3p and/or miR-485-5p we transfected
miRNA mimics for miR-210-3p and miR-485-5p in
SW872 and SK-UT-1 cells, after 24 h followed by the
transfection of the psiCHECK2/HIF3α 3’UTR luciferase
reporter constructs. Compared to the scrambled negative
control (mneg), miR-210-3p overexpression decreased the
luciferase activity to 36% and 41% in SW872 (Figure 4C,
left panel) and 37% and 43% in SK-UT-1 (Figure 4C, right
panel) in the HIF3α-short and HIF3α-long transfectants
respectively. MiR-485-5p overexpression reduced the
luciferase activity to 61% in the HIF3α-short construct
in the SW872 cell line. When ten additional putative bind-
ing sites for miR-485-5p were introduced in the HIF3α-
long transfectant, the luciferase activity dropped to 45%(Figure 4C, left panel). Overexpression of miR-485-5p de-
creased luciferase activity to 52% in SK-UT-1 cells trans-
fected with psiCHECK2/HIF3α-short and further reduced
luciferase activity to 24% in the HIF3α-long transfectants
(Figure 4C, right panel).
To prove whether the regulation of HIF3α is due to
direct binding of miR-210-3p and miR-485-5p to target
sites in the 3’UTR, the predicted binding sites were
mutated to prevent miRNA binding (Additional file 1:
Figure S1). Since the regulatory effect of the single miR-
485-5p site present in the HIF3α-short construct was
greater than the effect of the additional miR-485-5p
binding sites present in the HIF3α-long construct, only
the miR-485-5p target site in the HIF3α-short construct
was mutated. The presence of a mutated miR-210-3p
binding site significantly increased (SW872) or restored
(SK-UT-1) luciferase activity (Figure 4D). Mutation of
the miR-485-5p target site did not affect luciferase activ-
ity in SW872 cells and restored luciferase activity to
some extent in the SK-UT-1 cells. We conclude that
miR-210-3p directly regulates HIF3α whereas the regula-
tion observed with miR-485-5p is primarily due to an in-
direct effect. However, we cannot rule out that direct
regulation of HIF3α does occur mediated by one or
more of the additional miR-485-5p binding sites in the
HIF3α 3’UTR.
Discussion
STS, like all solid tumors, can present with hypoxic areas,
a state which is associated with disease progression and
Figure 4 (See legend on next page.)
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Figure 4 HIF3α is regulated by miR-210-3p and miR-485-5p. (A) MiR-210-3p and miR-485-5p mimic overexpression reduce HIF3α protein
induction under hypoxic conditions. The sarcoma cell lines SW872 and SK-UT-1 were transfected with mimics of miR-210-3p (m210), miR-485-5p
(m485) and a scrambled negative control mimic (mneg). 48 h post-transfection cells were cultured under hypoxic conditions (1% O2) for 24 h.
Subsequently total protein lysates were prepared and analysed by Western blotting for HIF3α protein expression. β-Actin is used as a loading
control. (B) Hypoxia responsive miRNAs target HIF3α 3’UTR. SW872 and SK-UT-1 cell lines were transfected with psiCHECK 2 constructs containing
short and long 3’UTR fragments of HIF3α. 24 h later the cells were exposed to hypoxia for 24 h. Bars indicate average luciferase activity ± SD
(n = 3) measured in hypoxic cell lysates relative to the luciferase activity in normoxic cell lysates which is arbitrarily set at 100. (C) MiR-210-3p and
miR-485-5p regulate HIF3α. SW872 and SK-UT-1 cell lines were transfected with mimics of miR-210-3p (m210), miR-485-5p (m485) or a scrambled
control mimic (mneg) followed after 24 h by a transfection with psiCHECK 2 constructs containing short and long fragments of the HIF3α 3’UTR.
Bars indicate average luciferase activity ± SD (n = 3) measured in cell lysates after 24 h. (D) MiR-210-3p and miR-485-5p regulate HIF3α. SW872
and SK-UT-1 cell lines were transfected with mimics of miR-210-3p (m210), miR-485-5p (m485) or a scrambled control mimic (mneg) followed,
after 24 h, by a transfection with a psiCHECK 2-HIF3α-short construct containing either wild-type (WT) or mutated (mut) miR-210-3p and
miR-485-5p binding sites. Bars indicate average luciferase activity ± SD (n = 3) measured in cell lysates. Statistical significance was determined by
two-sample t-tests: * = p < 0.05, ** = p < 0.005, *** = p < 0.0005.
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involvement of miRNAs in the hypoxic response of STS.
Greither et al. reported that the expression of miR-210-
3p, a well-known hypoxia responsive miRNA, is associ-
ated with poor survival in STS [39]. We identified 32
miRNAs that are deregulated upon hypoxia in a panel of
12 soft tissue sarcoma cell lines. Particularly, miR-185-
3p, miR-485-5p, miR-216a-5p were significantly upregu-
lated, while miR-625-5p was significantly downregulated.
In addition we detected induction of miR-210-3p upon
hypoxia using a RT-PCR procedure. In all cell lines ex-
amined, our array platform did not detect a significant
upregulation of miR-210-3p expression upon hypoxia. In
fact, expression levels detected were too low to be con-
sidered for subsequent analyses. This is most likely due
to the fact that the LNA capture probe for miR-210-3p
was not optimally designed. Exiqon varies both length
and LNA contents of the capture probes to obtain a Tm
normalized probe with appropriate affinity for its target
miRNA. Although the design and composition of the
capture probes are proprietary information we learned
that Exiqon has redesigned the miR-210-3p capture
probe in subsequent versions of the capture probe set. A
subset of the deregulated miRNAs, i.e. miR-185-3p, miR-
191, miR-210-3p, miR-373 (upregulated), miR-148b,
miR-181b and miR-342-5p (downregulated), was previ-
ously identified as hypoxia responsive miRNAs (HRM) in
other studies involving different cancer types [40-43].
These miRNAs may be regarded as general responders to
hypoxia. However the majority of miRNAs we detected
has not been previously associated with hypoxia suggest-
ing a cell-type specific miRNA response, as has been re-
ported before [25,44].
The molecular mechanisms responsible for miRNA
deregulation in response to hypoxia are for a large part
still unclear as is the precise role of each of the HRM in
the hypoxia response. As the key response to hypoxic
conditions is the stabilization of HIF1, HRMs can be
regulated by HIF-dependent or, alternatively, by HIF-independent mechanisms (reviewed in [44,45]). Some
HRMs, such as miR-210-3p, contain hypoxia responsive
elements (HREs) in their promoter region and are dir-
ectly regulated by the HIF1 transcription factor in re-
sponse to hypoxia [26,46,47]. Although HIF1 is generally
known as a transcriptional activator, it can also function
as a transcriptional repressor [48], which could account
for the downregulated miRNAs under hypoxic condi-
tions. Another HIF-dependent mechanism by which
hypoxia responsive miRNAs are regulated is via a HIF1
induced transcription factor, such as TWIST, which in-
duces miR-10b expression [49]. A HIF-independent
mechanism involved in the regulation of HRMs is e.g.
the induction of Akt2 upon hypoxia, which in turn upre-
gulates miR-21 [50]. Also deregulation of the miRNA
biogenesis during hypoxia could contribute to altered
miRNA expression levels. Recently it was reported that
hypoxia enhanced the association between EGFR and
Ago2, resulting in increased Ago2-phosphorylation and
reduced binding of Dicer to Ago2, thereby inhibiting
miRNA processing [51]. In contrast, in another study
hypoxia did not alter the expression of key miRNA ma-
chinery proteins (i.e. Drosha, Exp5, Dicer, Ago2 and
DP103) in human trophoblasts [52]. In order to deter-
mine whether our top hypoxia responsive miRNAs
(miR-185-3p; miR-485-5p; miR-216a-5p and miR-625-
5p) contain HREs in their putative promoter region we
screened 600 bp flanking sequences upstream of the
transcription start site of the primary miRNA. With the
exception of miR-485-5p of which the gene resides in a
densely packed miRNA cluster on chromosome 14, the
genes for miR-185-3p, miR-216a-5p and miR-625-5p are
not clustered. No consensus HRE (A/GCGTG) could be
detected upstream of miR-625-5p (which was downregu-
lated during hypoxia), whereas miR-216a-5p contains a
‘ACGTGC’(position -42 to -37) and miR-185-3p contains
a ‘CCGTG’(position -305 to -301). Although the latter
HRE does not perfectly match the consensus HRE se-
quence, imperfect HREs have been found to be functional
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miR-185-3p are regulated by HIF1.
Since miR-210-3p is considered a general responder to
hypoxia irrespective of cell-type and exact hypoxic con-
ditions, its function is thought to be universal. MiR-210-
3p has been demonstrated to have a role in e.g. cell
proliferation, angiogenesis, apoptosis, DNA repair and
mitochondrial metabolism (reviewed in [55-57]). The
function of other, less commonly deregulated HRMs is
poorly understood, but these miRNAs are likely to have
a cell-type specific function. Not much is known about
miR-485-5p. This miRNA was downregulated in ependy-
momas [58] and suppressed dendritic spine development
in rats [59]. Furthermore miR-485-5p was downregu-
lated in Alzheimers disease [60] and malignant serous
ovarian tumors, and correlated with FIGO grade in the
latter [61]. Computational analysis predicted as much as
eleven putative miR-485-5p binding sites in the 3’UTR
of HIF3α. Also miR-210-3p has a potential binding site
in the 3’UTR of this member of the family of hypoxia
inducible factors. Note that there are only two HIF3α
transcripts (variants 003 and 201) listed (http://www.
ensembl.org; release 72) that habor a 3’UTR long
enough to encompass all miR-485-5p binding sites in
addition to the miR-210-3p site. At least two other
HIF3α transcripts that contain a smaller 3’UTR (478 bp
in variant 006 and 287 bp in variant 007) also contain
the miR-210-3p binding site suggesting that the HIF3α
isoforms they encode may be controlled by miR-210-3p.
We demonstrated that HIF3α is regulated by miR-210-
3p and in an indirect fashion by miR-485-5p. We also
showed that HIF3α mRNA levels are induced upon hyp-
oxia as expected of a hypoxia inducible factor. Under
the same conditions, however, the expression of hypoxia
responsive miRNAs like miR-210-3p and miR-485-5p is
upregulated that affect HIF3α protein expression. We
postulate that miRNAs help to fine-tune HIF3α protein
expression and in this way regulate the cellular hypoxic
response. They can do so by affecting the translation of
specific HIF3α transcripts, however, we cannot rule out
that part of the regulation takes place via HIF3α mRNA
degradation. Although HRMs targeting HIF3α has never
been documented before, miRNA regulation of HIFs is
not uncommon: miR-155 [46], miR-424 [28], and the
miR-17-92 cluster [30] are known to target HIF1α. Thus
HIFs can induce the expression of miRNAs, and in turn,
miRNAs can also target HIFs.
Our understanding of the regulation of HIF3α and its
role in the hypoxic response is still rather limited. Re-
ports in the literature are sometimes contradictory or
difficult to compare as they focus on different HIF3α
splice variants in different cell types. It is clear that
HIF3α can be regulated at different levels. Transcription
of HIF3α can be induced by HIF via HREs in thepromoter region [5,7,11]. This probably accounts for the
increased HIF3α mRNA expression upon hypoxia. In
addition HIF3α can be regulated at the protein level.
HIF1α and HIF2α contain an oxygen dependent degrad-
ation domain (ODDD), which harbors two conserved
prolines that can be hydroxylated by prolyl hydroxylases
(PHDs) in presence of oxygen. This marks the proteins
for proteasomal degradation via the von Hippel-Lindau
(VHL) E3 ubiquitin ligase complex. It was postulated
that HIF3α, in contrast with HIF1α and HIF2α, is not
regulated at the level of protein stability, since the longer
HIF3α transcripts miss part of the ODDD and the
shorter isoforms lack the entire ODDD. This renders
them less prone to hydroxylation and subsequent pro-
teasomal degradation [11]. However, other studies
showed that the remaining proline residue in the ODDD
of HIF3α transcripts is targeted by VHL and subjected
to proteasomal degradation in an oxygen dependent
manner [5,6]. Besides transcriptional regulation of
HIF3α by HIF1 and oxygen dependent degradation of
HIF3α proteins, we provide evidence for an additional
layer of regulation of HIF3α, i.e. miRNAs that act on the
translational level. These different mechanisms can com-
plement one another in fine tuning HIF3α expression.
This may be critical because of the versatile role HIF3α
plays in the hypoxic response.
None of the HIF3α variants are likely to act as potent
transcription factors, since they lack a C-terminal trans-
activation domain. However, they can have an effect
on HRE-driven gene expression, depending on the level
of HIFβ [5,8,10]. When HIFβ is not limiting, it will
dimerize with HIF1α, HIF2α and HIF3α to induce a sub-
set of hypoxia regulated genes. HIF1α/HIFβ and HIF2α/
HIFβ complexes will associate with HRE sequences,
while the HIF3α/HIFβ complexes likely bind a response
element different from the canonical HRE, to maximize
hypoxia induced gene expression [5]. When HIFβ is lim-
iting, HIF3α will either compete with HIF1α and HIF2α
for binding with HIFβ [8], or HIF3α will associate with
HIF1α and HIF2α [5,10], both resulting in decreased
capability to bind HRE sequences and diminished tran-
scription of HIF target genes. As such, HIF3α splice vari-
ants will not act as global regulators of gene expressions,
but may modulate specific genes in a cell type dependent
manner [5,11].
Conclusion
In conclusion, this study describes, in addition to miR-
210-3p, a new panel of HRMs in hypoxic sarcoma cells.
In turn, two of these HRMs, i.e. miR-210-3p and miR-
485-5p, regulate HIF3α in a direct or indirect fashion,
respectively. Fine-tuning of HIF3α expression is of great
importance for the hypoxic response, since HIF3α affects
HIF1/2-induced gene expression. Keeping these negative
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adapt to hypoxic conditions. Deregulation of these mech-
anisms, e.g. by therapeutic modulation of levels of miR-
NAs that are important for the hypoxic response, may
inhibit the adaptive potential of the cells, and reduce
their resistance against radiation and systemic agents.
Additional file
Additional file 1: Table S1. Primers used for PCR and cloning. (A)
Primers used for end-point RT-PCRs of HIF3α 3’UTR fragments, resulting
in amplification products of 212 bp (Fw/Rv1) and 313 bp (Fw/Rv2).
Amplification of HPRT (product of 335 bp) was used as input control. (B)
Primers used for cloning HIF3α-short and HIF3α-long 3’UTR constructs.
(C) Primers used for site mutagenesis of predicted miR-485-5p and
miR-210-3p binding sites in HIF3α-short 3’UTR constructs. Table S2
Differentially expressed miRNAs (p<0.05) between cell lines that were
cultured under hypoxic and normoxic conditions. P-values of two-sample
t-test as well as fold change in miRNA expression and miRNA genomic
locations are indicated. False Discovery Rate (FDR) for the top four
miRNAs are: hsa-miR-185-3p (FDR 0.002893); hsa-miR-485-5p
(FDR 0.004466); hsa-miR-216a-5p (FDR 0.068687) and hsa-miR-625-5p
(FDR 0.112324). Figure S1 Predicted 3’UTR target sites in HIF3α for
miR-210-3p and miR-485-5p and the mutations that have been generated
in the target site sequence where the miRNA seed sequence (bold) binds.
The wild-type (WT) and mutated (mut) sites in HIF3α-short are shown.
The vertical lines represent possible base pairing between miRNA and
3’UTR target site, and the x’s indicate abrogated base pairing where
nucleotides are mutated (red). The resulting mutated 3’UTR fragments
were cloned into the psiCHECK-2 luciferase reporter.
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